Levosimendan for Weaning from Cardiopulmonary Bypass after Coronary Artery Bypass Grafting

Akgül, Ahmet; Mavioğlu, Levent; Katırcıoğlu, Salih Fehmi; Paç, Mustafa; Çobanoğlu, Adnan

doi:10.1016/j.hlc.2006.05.014

Cited by 14 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numerous uncontrolled case series have indicated that levosimendan results in increased CI and reduced pulmonary capillary wedge pressure (PCWP) when given alone or in combination with catecholamines [12][13][14][15]. When compared to placebo, levosimendan increased cardiac output at unaltered myocardial oxygen consumption and without increase in arrhythmias [16,17].…”

Section: Discussionmentioning

confidence: 99%

Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function

Kolseth

Nordhaug

Stenseth

et al. 2009

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function

Kolseth

Nordhaug

Stenseth

et al. 2009

European Journal of Cardio-Thoracic Surgery

View full text Add to dashboard Cite

show abstract

“…Bir çok ça lış ma da levo si men da nın kar di yo pul mo ner by-pass son ra sı kar di yak per for man sı ar tır dı ğı ve sol ven tri kül ard yü kü nü azalt tı ğı gös te ril miş tir. [14][15][16][17] Her iki ol gu da da le vo si men dan kul la nı mı intra o pe ra tif dö nem de dü şük de bi ye bağ lı olu şan hemo di na mik tab lo nun dü zel me sin de yar dım cı olmuş tur. Le vo si men da nın göz le nen en sık yan et kisi olan sis te mik hi po tan si yon bu ol gu lar da göz lenme miş tir.…”

Section: 2unclassified

Levosimendan Treatment During Orthotopic Heart Transplantation: Case Report

Durak¹,

Yağar²,

Uzuner³

2010

Turkiye Klinikleri J Med Sci

View full text Add to dashboard Cite

show abstract

“…Several preclinical and clinical studies have supported this conclusion. 15,[89][90][91][92][93][94][95][96][97][98][99] …”

Section: Clinical Studies With Levosimendan Implicating Favorable Myomentioning

confidence: 99%

Effects of Levosimendan on the Energy Balance: Preclinical and Clinical Evidence

Nieminen

Pollesello²,

Vajda

et al. 2009

Journal of Cardiovascular Pharmacology

View full text Add to dashboard Cite

Levosimendan is a novel inodilator agent, which enhances myocardial performance without substantial changes in oxygen consumption. The combination of positive inotropic and vasodilator effects of levosimendan relates to its Ca-sensitizing and K channel opening effects. Levosimendan is one of the best documented pharmacological agents used in the management of acute heart failure syndromes. Interest in levosimendan has recently been renewed owing to its potential in supporting cardiac function in patients with ischemic heart disease and cardiogenic or septic shock. It has been also demonstrated that levosimendan can be used as a bridge therapy for the perioperative phase of cardiac surgery. The ability of levosimendan to improve myocardial function without substantially increasing oxygen consumption may appear paradoxical but is indeed possible via improved efficacy, not only with regard to the effects on the contractile apparatus of the cardiomyocytes but also when its composite hemodynamic effects are considered. The energy balance equation, therefore, should take into account the effect of levosimendan on all energy-consuming and energy-producing paths. Moreover, levosimendan-evoked KATP channel opening may possess favorable effects on mitochondrial adenosine triphosphate synthesis conferring cardioprotection during ischemic insults.

show abstract

Levosimendan for Weaning from Cardiopulmonary Bypass after Coronary Artery Bypass Grafting

Cited by 14 publications

References 19 publications

Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function

Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function

Levosimendan Treatment During Orthotopic Heart Transplantation: Case Report

Effects of Levosimendan on the Energy Balance: Preclinical and Clinical Evidence

Contact Info

Product

Resources

About